Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neuroendocrine Tumor, Malignant”

803 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 803 results

Testing effectiveness (Phase 2)Study completedNCT03008369
What this trial is testing

Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery

Who this might be right for
Malignant Adrenal Gland PheochromocytomaMalignant ParagangliomaMetastatic Adrenal Gland Pheochromocytoma
Mayo Clinic 3
Early research (Phase 1)Study completedNCT00101270
What this trial is testing

Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

Who this might be right for
Childhood Burkitt LymphomaChildhood Central Nervous System Germ Cell TumorChildhood Diffuse Large Cell Lymphoma+26 more
National Cancer Institute (NCI) 24
Very early researchEnded earlyNCT03060356
What this trial is testing

Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)

Who this might be right for
Malignant MelanomaBreast Cancer
University of Pennsylvania 77
Large-scale testing (Phase 3)Study completedNCT01359956
What this trial is testing

Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma

Who this might be right for
Malignant MelanomaRecurrent Melanoma
National Cancer Institute, Naples 269
Testing effectiveness (Phase 2)Study completedNCT06152367
What this trial is testing

Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients

Who this might be right for
Stage III Malignant Melanoma of Skin AJCC V6Stage IV Malignant Melanoma of Skin
University of Chile 90
Early research (Phase 1)Study completedNCT02680184
What this trial is testing

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

Who this might be right for
Melanoma
Regeneron Pharmaceuticals 199
Testing effectiveness (Phase 2)WithdrawnNCT05572463
What this trial is testing

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Who this might be right for
Unresectable Cutaneous MelanomaMetastatic Cutaneous Melanoma
Innovent Biologics (Suzhou) Co. Ltd.
Testing effectiveness (Phase 2)Study completedNCT00458952
What this trial is testing

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Who this might be right for
PheochromocytomaParaganglioma
Molecular Insight Pharmaceuticals, Inc. 24
Testing effectiveness (Phase 2)Study completedNCT00204594
What this trial is testing

Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28

Who this might be right for
Malignant Melanoma
University Hospital Tuebingen 1
Not applicableLooking for participantsNCT01365169
What this trial is testing

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

Who this might be right for
Malignant Head and Neck NeoplasmMalignant NeoplasmMetastatic Malignant Neoplasm in the Neck+45 more
M.D. Anderson Cancer Center 590
Early research (Phase 1)Active Not RecruitingNCT02589522
What this trial is testing

Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors

Who this might be right for
Metastatic Lung Neuroendocrine NeoplasmMetastatic Lung Non-Small Cell CarcinomaMetastatic Lung Small Cell Carcinoma+4 more
National Cancer Institute (NCI) 15
Testing effectiveness (Phase 2)WithdrawnNCT05582031
What this trial is testing

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers

Who this might be right for
Anal Squamous Cell CarcinomaColorectal NeoplasmsSoft Tissue Sarcoma+5 more
Translational Research in Oncology
Testing effectiveness (Phase 2)WithdrawnNCT03448666
What this trial is testing

ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases

Who this might be right for
Malignant Melanoma
European Institute of Oncology
Not applicableApproved For MarketingNCT02961491
What this trial is testing

Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Who this might be right for
PheochromocytomaParaganglioma
Molecular Insight Pharmaceuticals, Inc.
Large-scale testing (Phase 3)Study completedNCT01006980
What this trial is testing

Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 675
Testing effectiveness (Phase 2)Study completedNCT00036764
What this trial is testing

BMS-247550 in Treating Patients With Stage IV Melanoma

Who this might be right for
Recurrent MelanomaStage IV Melanoma
National Cancer Institute (NCI) 88
Early research (Phase 1)Study completedNCT01522664
What this trial is testing

DEDN6526A in Patients With Metastatic or Unresectable Melanoma

Who this might be right for
Malignant Melanoma
Genentech, Inc. 53
Testing effectiveness (Phase 2)Looking for participantsNCT06176989
What this trial is testing

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

Who this might be right for
Metastatic ChondrosarcomaLocally Advanced ChondrosarcomaMetastatic Sinonasal Adenocarcinoma+7 more
National Cancer Institute (NCI) 40
Very early researchWithdrawnNCT04223648
What this trial is testing

Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Yale University
Early research (Phase 1)Study completedNCT00161187
What this trial is testing

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Who this might be right for
Cancer
University of Medicine and Dentistry of New Jersey 37
Load More Results